Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda
Retrieved on:
Thursday, October 19, 2023
Biomedical Advanced Research and Development Authority, Guinea, Makerere University Walter Reed Project, Sabin Vaccine Institute, Vaccine, Family, Human services, Kenya Medical Research Institute, Administration for Strategic Preparedness and Response, Viral hemorrhagic fever, Organization, BARDA, United States Department of Health and Human Services, Research, Volunteering, Administration, Development, Epidemic, Disease, Clinical trial, Blood, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Polio, Marburg virus disease, Medical device, Pharmaceutical industry
WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers received the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda today.
Key Points:
- WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus.
- “Makerere University Walter Reed Project (MUWRP) is delighted to partner with the Sabin Vaccine Institute to launch the clinical testing for a preventive Marburg vaccine,” says Dr. Mwesigwa.
- In addition to the current trial in Uganda and Kenya, Sabin plans to conduct a similar Phase 2 clinical trial for Marburg in the U.S.
- Sabin has also initiated plans for a Phase 2 Sudan ebolavirus vaccine clinical trial in Uganda and Kenya.